The subsidiary, Clover Therapeutics, plans to use members’ data to help inform the development of new therapies for age-related chronic diseases.
Clover Therapeutics signed an initial partnership with biotechnology company Genentech to study the genomic factors of such eye diseases as macular degeneration. The knowledge gained also will identify patients most likely to benefit from treatment.
“Clover Therapeutics was created to address the significant unmet needs in chronic progressive diseases in the Medicare population,” said Cheng Zhang, head of Clover Therapeutics. “By partnering with our members to study the clinical and genetic drivers of ocular diseases, combined with Genentech’s pioneering history of drug discovery and development in this area, we hope to improve the quality of life for seniors living with these conditions.”
More articles on pharmacy:
Judge blocks HHS rule requiring drug prices in TV ads
Nation’s 1st prescription drug affordability board goes into effect
11 healthcare pharma leaders offer advice on controlling drug spend
At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.